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FragileX-associated tremor/ataxiasyndrome (FXTAS)
is a neurodegenerative disorder caused by a
limited expansion of CGG repeats in the 50 UTR
of FMR1. Two mechanisms are proposed to
cause FXTAS: RNA gain-of-function, where CGG
RNA sequesters specific proteins, and transla-
tion of CGG repeats into a polyglycine-containing
protein, FMRpolyG. Here we developed trans-
genic mice expressing CGG repeat RNA with or
without FMRpolyG. Expression of FMRpolyG is
pathogenic, while the sole expression of CGG
RNA is not. FMRpolyG interacts with the nuclear
lamina protein LAP2b and disorganizes the nuclear
lamina architecture in neurons differentiated from
FXTAS iPS cells. Finally, expression of LAP2b
rescues neuronal death induced by FMRpolyG.
Overall, these results suggest that translation of
expanded CGG repeats into FMRpolyG alters nu-
clear lamina architecture and drives pathogenesis
in FXTAS.Neuron 93, 331–347, Jan
This is an open access article under the CC BY-NINTRODUCTION
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a
neurodegenerative disorder caused by a pre-mutation of 55 to
200 CGG repeats in the 50 untranslated region (UTR) of the fragile
X mental retardation 1 (FMR1) gene (Hagerman et al., 2001). The
carrier prevalence of the CGGpre-mutation is approximately 1 of
200 females and 450 males, but due to incomplete pene-
trance, it is estimated that 1 in 3,000 men older than 50 years
will develop FXTAS (Jacquemont et al., 2004; Tassone et al.,
2012). The clinical features of FXTAS include progressive inten-
tion tremor and gait ataxia, frequently accompanied by progres-
sive cognitive decline, parkinsonism, peripheral neuropathy, and
autonomic dysfunctions (Jacquemont et al., 2003). Principal
neuropathologies of FXTAS include mild brain atrophy and white
matter lesions with the presence of ubiquitin-positive nuclear
neuronal and astrocytic inclusions (Greco et al., 2006). In
contrast to fragile X syndrome, where expanded full mutation
alleles (>200 CGG repeats) result in hypermethylation and
silencing of the FMR1 gene, FXTAS carriers of pre-mutation
expanded alleles (55–200CGG repeats) present increased levels
of FMR1 mRNA but slightly reduced expression of the protein
encoded by FMR1, FMRP (Tassone et al., 2000, 2007; Kenneson
et al., 2001).uary 18, 2017 ª 2017 The Author(s). Published by Elsevier Inc. 331
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Because FXTAS is not observed in fragile X patients with fully
silenced FMR1 alleles, a pathogenic mechanism based on
expression of mutant FMR1 mRNAs containing expanded
CGG repeats has been proposed (Hagerman and Hagerman,
2004). In support of this hypothesis, multiple studies have
demonstrated adverse consequences of expressing RNA con-
taining expanded CGG repeats in cell, fly, and mouse models
(Willemsen et al., 2003; Jin et al., 2003; Arocena et al., 2005;
Hashem et al., 2009; Entezam et al., 2007; Hukema et al.,
2014, 2015). However, how FMR1 mRNA containing expanded
CGG repeats is pathogenic is unclear. A first proposed model
is that FXTAS results from a toxic RNA gain-of-function mecha-
nism in which mutant RNA containing expanded CGG repeats
sequesters specific RNA binding proteins, resulting in neuronal
cell dysfunctions (Iwahashi et al., 2006; Sofola et al., 2007; Jin
et al., 2007; Sellier et al., 2010, 2013). A second proposed mech-
anism is that FXTAS is caused by repeat-associated non-AUG
(RAN) translation of the expanded CGG repeats into polyalanine-
and polyglycine-containing proteins named FMRpolyA and
FMRpolyG (Todd et al., 2013). Ranum and colleagues originally
demonstrated that expanded CAG repeats can be translated in
all three frames in the absence of any AUG initiation codon (Zu
et al., 2011). Subsequently, RAN translation was described and
proposed as a causative mechanism in various inherited micro-
satellite neurodegenerative disorders (reviewed in Cleary and
Ranum, 2014), including FXTAS (Todd et al., 2013; Kearse
et al., 2016). However, the mechanism and the pathological con-
sequences of translating expanded CGG repeats are not fully
understood. Specifically, which pathological mechanism (RNA
gain-of-function or RAN translation) drives FXTAS pathogenesis
is a crucial question.
Here we find that translation of expanded CGG repeats occurs
predominantly in the glycine frame through initiation at a near-
cognate ACG codon located upstream of the expanded CGG re-
peats. Importantly, transgenic mice expressing both CGG RNA
repeats and the polyglycine protein (FMRpolyG mouse), but
not mice expressing only the mutant RNA containing expanded
CGG repeats (CGG RNA mouse), exhibit inclusion formation,
motor phenotypes, and reduced lifespan. FMRpolyG interacts
with LAP2b, a protein essential to anchoring lamin proteins to
the inner nuclear membrane, and overexpression of LAP2b res-
cues neuronal cell death induced by expression of FMRpolyG.
Overall, these results suggest that translation of expanded
CGG repeats into FMRpolyG, which alters nuclear lamina, may
contribute to FXTAS.
RESULTS
Translation of Expanded CGG Repeats Initiates at an
Upstream Near-Cognate Codon
To confirm previous observations of translation of expanded
CGG repeats in the absence of an AUG start codon (Todd
et al., 2013; Kearse et al., 2016), we cloned 100 CGG repeats
embedded within the natural human 50 UTR of FMR1, which
was fused to the GFP deleted of its ATG and in all three possible
frames (Figure S1A). These frames were named according to the
polypeptide potentially encoded by the expanded CGG re-
peats—namely, glycine, alanine, and arginine. Cell transfection332 Neuron 93, 331–347, January 18, 2017and immunoblotting against GFP confirm previous data (Todd
et al., 2013; Kearse et al., 2016) and demonstrate that the
50 UTR of FMR1 with expanded CGG repeats allows translation
of a GFP protein with an 12 kDa N-terminal extension corre-
sponding to the expanded CGG repeats translated into the
glycine frame (Figure 1A and Figure S1B). In contrast, we
observed no translation when the FMR1 sequence located up-
stream of the repeats was deleted (Figure 1A and Figure S1B).
Serial deletions confirmed that a short FMR1 sequence located
upstream of the CGG repeats was required for FMRpolyG trans-
lation (Figure 1B). Treatment with Lysostaphin, a polyglycine
endopeptidase, confirmed that expanded CGG repeats are
translated into a polyglycine-containing protein (Figure S1C).
To further characterize the initiation site of expanded CGG
repeat translation, we immunoprecipitated FMRpolyG and
determined its N-terminal sequence by proteomic analysis after
trypsin digestion. LC-MS/MS spectra revealed initiation to an
ACG near-cognate codon located 32 nucleotides upstream of
the CGG expansion (Figure 1C). To exclude any bias of diges-
tion, we repeated this experiment with a construct containing a
mutation in which a lysine (sensitive to the LysC enzyme) is pre-
sent upstream of the expanded CGG repeats, but the remaining
sequence, notably the ACG codon, is untouched. Proteomic
analysis of FMRpolyG after LysC digestion confirmed that
FMRpolyG translation initiates at the ACG near-cognate codon
(Figure S1D). Of interest, proteomic analysis also revealed that
the initial amino acid of FMRpolyG is a methionine, suggesting
that the ACG codon is decoded by an initiator Met-tRNA despite
imperfect match (Figures 1C and S1D). This ACG near-cognate
codon is embedded in a putative Kozac consensus sequence
that is conserved among multiple species (Figure S1E). Transla-
tion initiation at the ACG near-cognate codon is predicted to
result in a small FMRpolyG protein composed of a short, 12-
amino-acid N terminus, a central glycine stretch with a length
that corresponds to the number of expanded CGG repeats,
and a C terminus of 42 amino acids with no predicted structure
or homology (Figure 1D). Thus, according to the number of
CGG repeats, FMRpolyG may range from 7 kDa in control indi-
viduals with 30 CGG repeats to 15 kDa in carriers of pre-muta-
tion with 150 CGG repeats.
A Minimum of 60 to 70 Expanded CGG Repeats Is
Required to Detect FMRpolyG
Upstream ORFs (uORFs) are short open reading frames that are
located in the 50 UTR of mRNAs upstream of the main ORF. Due
to the 50 to 30 scanning ribosome process, and in absence of
ribosome re-initiation, the translation of a uORF generally impairs
translation of the downstream main ORF. To avoid complete
translation inhibition, uORFs typically start by an AUG or a
near-cognate codon (GUG, CUG, UUG, ACG, etc.) embedded
in a poor Kozac consensus sequence that enables leaky ribo-
somal scanning and hence translation initiation at the down-
stream main ORF (reviewed in Sonenberg and Hinnebusch,
2009). To test the presence of a putative uORF encompassing
the CGG repeats in FMR1, we cloned various lengths of CGG
expansion within the human 50 UTR of FMR1 fused in the glycine
frame with a small FLAG tag (eight amino acids, 1 kDa). Immu-
noblotting revealed that expression of FMRpolyG-FLAG is
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Figure 1. Translation of CGG Repeats Initiates at an Upstream Near-Cognate Codon
(A) Immunoblotting against GFP on the soluble lysate fraction of HeLa cells transfected for 24 hr with expanded CGG repeats embedded, or not, in the 50 UTR of
FMR1 and fused in all three possible frames with the GFP deleted of its ATG.
(B) Upper, schemes of the FMR1 50 UTR deletion constructs tested. Middle, immunoblotting against GFP on the soluble lysate fraction of HeLa cells transfected
for 24 hr with mutants of FMR1 50 UTR containing expanded CGG repeats fused to the GFP in the glycine frame. Lower, quantification of FMRpolyG-GFP
expression reported to GAPDH.
(C) LC-MS/MS spectra of the N-terminal part of the immunoprecipitated and trypsin-digested protein translated from expanded CGG embedded in the 50 UTR
of FMR1.
(D) Scheme and partial nucleotide sequence of human FMR1 exons 1 and 2. Amino acid sequence of FMR1 uORF translated into FMRpolyG is indicated in red.
Amino acid sequence of the beginning of the FMRP ORF is indicated in green.
Error bars indicate SEM of three independent transfections. Student’s t test, *** indicates p < 0.001.
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Figure 2. A Minimum of 60 Expanded CGGRepeats
Is Required to Detect FMRpolyG
(A) Upper, immunoblotting against the FLAG tag on the
soluble lysate fraction of HeLa cells transfected for 24 hr
with various lengths of expanded CGG repeats embedded
in the 50 UTR of FMR1 and fused in the glycine frame with
the FLAG tag. Middle, control immunoblotting against
GAPDH. Lower, quantification of FMRpolyG-FLAG levels
reported to GAPDH.
(B) Identical to (A), but with CGG repeats embedded in the
50 UTR of FMR1 fused in the glycine frame with a GFP tag
instead of a FLAG tag.
(C) Left, schemes of the 50 UTR of FMR1 constructs with
ACG mutations. FMRpolyG uORF is FLAG-tagged in the
glycine frame, while FMRP ORF is GFP-tagged. Right,
upper, and middle, immunoblotting against FLAG, GFP,
and GAPDH on the soluble lysate fraction of HeLa cells
transfected for 24 hr with mutants of the 50 UTR of FMR1;
expanded CGG repeats are fused to the FLAG tag in the
glycine frame, while the downstream FMRP ORF is fused
to the GFP. Right lower, quantification of FMRpolyG-FLAG
and FMRP-GFP levels reported to GAPDH.
(D) Immunofluorescence against the FMRpolyGN terminus
and ubiquitin on brain sections (hippocampal area) of
FXTAS or control individuals. Scale bars, 10 mm. Nuclei
were counter-stained with DAPI.
(E) Immunoblotting against the FMRpolyG N terminus of
insoluble fraction of brain lysate (cerebellum area) of
FXTAS and age-matched individuals.
The numbers of expanded CGG in FMR1 are indicated
as # CGG. Error bars indicate SEM of three independent
transfections. Student’s t test, * indicates p < 0.05, *** in-
dicates p < 0.001.detected only with expanded CGG repeats over 60 to 70 CGG
repeats (Figure 2A), the threshold over which pre-mutation car-
riers are at risk of developing FXTAS. Fusion of expanded CGG
repeats in the glycine frame to the GFP (25 kDa) confirmed that
translation occurred with expanded CGG repeats of various
lengths (70 to 100 repeats), characteristic of pre-mutation car-
riers (Figure 2B). However, FMRpolyG-GFP was also translated
with short stretches of CGG repeats (30) found in control individ-
uals or even without any CGG repeats (Figure 2B). These results
suggest that translation initiation occurs at the ACG near-
cognate codon independently of the CGG repeats but that
expansion over 70 repeats is important for detection of
FMRpolyG. This is characteristic of short upstream ORFs that
are generally translated into small and most often undetectable
peptides but which are detected when fused with large tags, re-
sulting in stable and detectable proteins (Aspden et al., 2014).
Next, we noted that FMRpolyG and FMRP ORFs are in
different frames, with the last 20 amino acids of FMRpolyG natu-334 Neuron 93, 331–347, January 18, 2017rally overlapping the FMRP N terminus (Fig-
ure 1D). Thus, translation of the FMRpolyG
uORF may potentially impair ribosomal re-initia-
tion to the downstream FMRP ORF. To test that
hypothesis, we fused the 50 UTR of FMR1 to a
FLAG tag in the glycine frame and also fused
the downstream FMRP ORF in frame with the
GFP (Figure 2C). This construct expresses theFLAG-tagged FMRpolyG uORF or the downstream GFP-tagged
FMRP main ORF (Figure 2C), suggesting that translation initia-
tion occurs either at the FMRpolyG ACG near-cognate codon
or at the FMRP ATG codon. Deletion of the 50 UTR sequence
containing the ACG near-cognate initiation codon abolished
expression of the FLAG-tagged FMRpolyG uORF but enhanced
translation of the downstream GFP-tagged FMRP ORF (Fig-
ure 2C). In contrast, mutation of the ACG near-cognate codon
into a cognate AUG initiation codon predictably enhanced
translation of the FLAG-tagged FMRpolyG uORF, but abol-
ished expression of the downstream, GFP-tagged FMRP ORF
(Figure 2C).
To confirm that FMRpolyG is encoded by an ORF initiating up-
stream of the CGG repeats, we developed an antibody directed
against the 12 amino acids located upstream of the glycine re-
peats (Figure S2A). Immunofluorescence revealed the presence
of FMRpolyG N terminus in brain sections of FXTAS patients, but
not in age-matched control individuals (Figure 2D). FMRpolyG
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Figure 3. Expression of FMRpolyG Is Pathogenic in Mice
(A) Schemes of the mouse transgene constructs.
(B) Quantitative RT-PCR analysis of transgene expression relative to the RplpOmRNA in different brain areas and tissues of 6-month-old control (n = 3), bigenic
CMV-cre/full-length (n = 3), or mutant (n = 3) FMR1 50 UTR transgenic mice.
(C) Immunohistochemistry against FMRpolyG N terminus of cerebellum and hippocampus areas of 6-month-old bigenic CMV-cre/full-length or mutant FMR1
50 UTR transgenic mice. Scale bars, 10 mm. Sections were counter-stained with Nissl staining.
(D) Immunofluorescence against FMRpolyG N terminus and ubiquitin on cerebellum areas of 6-month-old bigenic CMV-cre/full-length or mutant FMR1 50 UTR
transgenic mice. Scale bars, 10 mm. Nuclei were counter-stained with DAPI.
(E) Rotarod test: the time before falling from a rotating rod of 3-month-old control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9) FMR1 50 UTR
transgenic male mice.
(legend continued on next page)
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N terminus is detected as single nuclear inclusions that co-
localize with ubiquitin, which is consistent with the known histo-
pathological features of FXTAS (Greco et al., 2006). We
confirmed these results by immunoblotting and found that, ac-
cording to the size of the CGG expansion, FMRpolyG was de-
tected as a 10- to 14-kDa protein in the insoluble fraction of brain
lysate of FXTAS individuals (Figure 2E). The poor quality of the
immunoblotting is probably due to the propensity of this
glycine-rich protein to aggregate. To ensure that translation suc-
cessfully passes across the expanded CGG repeats, we also
developed an antibody against the amino acids located down-
stream of the glycine repeats (Figure S2A). Consistent with
previous analyses (Todd et al., 2013; Buijsen et al., 2014), immu-
nofluorescence confirmed presence of FMRpolyG C terminus in
brain sections of FXTAS patients, but not in age-matched control
individuals (Figure S2B). Finally, translation of expanded CGG
repeats into a polyalanine-containing protein was reported pre-
viously (Todd et al., 2013; Kearse et al., 2016). We developed
an antibody against the putative C-terminal part of this protein
(Figure S2C), but observed no or very little FMRpolyA in individ-
uals with FXTAS (Figure S2D).
Translation of Expanded CGG Repeats into FMRpolyG Is
Pathogenic in Mice
The presence of both CGG RNA aggregates, which can titrate
out RNA binding proteins, and FMRpolyG–positive inclusions
in individuals with FXTAS raises the question of which patho-
genic mechanism is driving neuronal degeneration in this
disease. To differentiate between these two hypotheses, we
developed two transgenic mouse models. The first one contains
the full human 50 UTR of FMR1 with expanded 99 CGG repeats
that express both CGG RNA and FMRpolyG protein, while the
second mouse model also expresses 99 CGG repeats, but the
non-canonical ACG initiation codon and surrounding 50 UTR
sequence are deleted so it only expresses the CGG RNA (Fig-
ure 3A). Both constructs are driven by a chimeric CAG promoter
inserted within the neutral Rosa26 locus and under repression of
a loxP-polyadeneylation cassette (Figure 3A).
Deletion of the loxP cassette using a ubiquitously and embry-
onically expressed Cre recombinase led to high expression of
transgene RNA throughout the brain, heart, and liver, with lower
expression in skeletal muscle, kidneys, and other organs (Fig-
ure 3B). Importantly, transgene RNA expression was similar in bi-
genic CMV-cre mice with either the full or mutant FMR1 50 UTR
(Figure 3B). However, we found no or only very rare CGG RNA
foci in brain sections of full or mutant FMR1 50 UTR transgenic(F) String test: the time to gain hindlimb traction for forelimb-hanging 3-month-o
50 UTR transgenic male mice.
(G) Grip test: the maximal force relative to mouse body weight exerted to release 3
FMR1 50 UTR transgenic male mice holding a grid with their forepaws.
(H) Open field: number of rears during 5 min observation in open field of 3-month
50 UTR transgenic male mice.
(I) Body weight of 2-, 4-, and 6-month-old control (n = 6), bigenic CMV-cre/full-le
(J) Left, immunofluorescence labeling of calbindin of cerebellum sections of 9-mo
Scale bars, 10 mm.Nuclei were counter-stainedwith DAPI. Right, quantification of
full-length (n = 3) or mutant FMR1 50 UTR (n = 3) transgenic mice.
(K) Kaplan-Meier survival curve of control (n = 15), bigenic CMV-cre/full-length (n
Error bars indicate SEM. Student’s t test, * indicates p < 0.05, ** indicates p < 0.
336 Neuron 93, 331–347, January 18, 2017mice (Figures S3A and S3B). This is consistent with the rare
occurrence of CGG RNA aggregates in other transgenic mouse
models expressing expanded CGG repeats (Sellier et al., 2010).
Concerning the FMRpolyG protein, immunohistochemistry as-
says demonstrated expression and accumulation of nuclear ag-
gregates of FMRpolyG in brain sections from the full 50 UTR
FMR1 transgenic mice, but not in the mutant 50 UTR mice (Fig-
ures 3C and S3C). These results confirm in mouse models that
translation of the CGG repeats in the glycine frame requires
the presence of an upstream FMR1 sequence. As observed
in brain samples of individuals with FXTAS, aggregates of
FMRpolyG in mice co-localized with ubiquitinated inclusions
(Figure 3D). Nuclear aggregates of FMRpolyG accumulated
over time, with the largest burden of inclusions occurring within
the hypothalamus, mirroring transgene RNA expression (Figures
S3C and S3D). Some rare aggregates of FMRpolyG were found
in other tissues than brain, which is reminiscent of reported
FMRpolyG aggregates in non-CNS tissues in FXTAS patients
(Buijsen et al., 2014). In contrast, we did not observe aggregates
of FMRpolyA in the full or mutant 50 UTR mice (Figure S3E).
To determine the consequences of FMRpolyG production in
mice, we conducted a series of behavioral and locomotor assays
on both mouse lines. Mice with the full 50 UTR of FMR1 develop
obesity at 6 months of age. Therefore, behavioral tests were per-
formed at 3 months of age when weight is identical between full
and mutant FMR1 50 UTR transgenic mice. Importantly, we
observed that only mice with both the full 50 UTR sequence of
FMR1 and expression of the FMRpolyG protein present locomo-
tor deficiency (Movies S1 and S2), with increased falling from ro-
tarod (Figure 3E), decreased ability of traction from the hind
limbs (Figure 3F), decreased grip strength (Figure 3G), and a
decreased number of rears in open field observation (Figure 3H).
At 6 months of age, mice with the full 50 UTR of FMR1 lose
mobility and develop obesity, while mice with the mutant
50 UTR that express only the CGGRNA remain normal (Figure 3I).
We did not observemassive neuronal cell death, but found some
loss of Purkinje cells in mice with the full 50 UTR of FMR1
compared to mutant 50 UTR mice (Figures 3J and S3F). Further-
more, Iba1 and Gfap staining were mildly increased in brain sec-
tions of mice with the full 50 UTR of FMR1 compared to mutant
50 UTR mice, suggesting some increased neuroinflammation in
FMRpolyG-expressing animals (Figure S3G). Finally, expression
of FMRpolyG is deleterious, as mice expressing the full 50 UTR of
FMR1 die at around 10 months, while mutant FMR1 50 UTRmice
exhibit normal longevity and are indistinguishable from control
mice (Figure 3K).ld control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9) FMR1
-month-old control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9)
-old control (n = 8), bigenic CMV-cre/full-length (n = 9), or mutant (n = 9) FMR1
ngth (n = 6), or mutant (n = 6) FMR1 50 UTR transgenic male mice.
nth-old bigenic CMV-cre/full-length or mutant FMR1 50 UTR transgenic mice.
Purkinje cells (n = 100) in cerebellum sections of 9-month-old bigenic CMV-cre/
= 15), or mutant (n = 15) FMR1 50 UTR male and female transgenic mice.
01 and *** indicates p < 0.001.
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Figure 4. Neuronal Expression of FMRpolyG Is Pathogenic in Mice
(A) Schemes of the mouse transgene constructs.
(B) Quantitative RT-PCR analysis of transgene expression relative to the RplpO mRNA in different tissues of 6-month-old control (n = 3), bigenic CMV-cre/full-
length FMR1 50 UTR (n = 3), or bigenic Nestin-cre full-length FMR1 50 UTR (n = 3) mice.
(C) Immunohistochemistry against FMRpolyG N terminus in the cerebellum, hippocampus, and hypothalamus of 6-month-old bigenic Nestin-cre/full-length
FMR1 50 UTR mice. Scale bars, 10 mm. Sections were counter-stained with H&E staining.
(D) Rotarod test: time before falling of 3-month-old control (n = 6) or bigenic Nestin-cre/full-length FMR1 50 UTR (n = 6) male mice.
(E) Left, immunohistochemistry against calbindin of cerebellum sections of 10-month-old control or bigenic Nestin-cre/full-length FMR1 50 UTRmice. Scale bars,
10 mm. Sections were counter-stained with H&E staining. Right, quantification of Purkinje cells (n = 50) in cerebellum sections of 10-month-old control (n = 3) or
bigenic Nestin-cre/full-length FMR1 50 UTR (n = 3) mice.
(F) Immunohistochemistry against Gfap of hippocampal sections of 10-month-old control or bigenic Nestin-cre/full-length FMR1 50 UTR mice.
(legend continued on next page)
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To assess the tissue origin of these phenotypes, we next
analyzed offspring of full 50 UTR transgenic mice crossed with
Nestin-cre mice, which express the Cre recombinase in precur-
sors of neurons and glia cells around E10.5 (Figure 4A). Quantita-
tive RT-PCR revealed high expression of expanded CGG RNA
only in mouse brain of the double transgenic Nestin-cre/full
50 UTR FMR1 mice, confirming the specificity of the Nestin pro-
moter (Figure 4B). Immunohistochemistry indicated expression
and accumulation of nuclear aggregates of FMRpolyG in brain
sections of these bigenicmice, but not in control, non-transgenic
animals (Figures 4C and S4A). Importantly, locomotor testing
at 3 months of age revealed increased falling from rotarod
compared to control, non-transgenic mice (Figure 4D). Histo-
pathological analyzes revealed somePurkinje cell loss (Figure 4E)
and evidence of neuroinflammation (Figure 4F) in 9- to 10-month-
old Nestin-cre/full 50 UTR FMR1 mice compared to control ani-
mals. Interestingly, mice expressing FMRpolyG only in the brain
developed obesity (Figure 4G) and exhibited reduced longevity
(Figure 4H), similar to the CMV-cre/full 50 UTR FMR1 mice. The
obesity developed by thesemicemay originate from dysfunction
of the hypothalamus, as this area is the one expressing the most
and the earliest FMRpolyG. In support of that hypothesis, RT-
qPCR indicated that expression of the leptin receptor, which is
essential to regulate energy balance by inhibiting hunger, was
decreased in the hypothalamic area of these mice (Figure S4B).
The 50 UTR Sequence of FMR1 Impairs Formation of
Expanded CGG-Repeat RNA Foci
The absence of RNA foci of expanded CGG repeats in full and
mutant 50 UTR FMR1 mice is puzzling, as FXTAS is proposed
to result from nuclear accumulation of mutant CGG RNA that
would sequester various RNA binding proteins. Thus, we tested
whether transfection of expanded CGG repeats embedded in
their natural FMR1 50 UTR sequence would form any RNA foci
in mouse neuronal cell cultures. As positive control, we used a
construct expressing expanded CGG repeats without the sur-
rounding FMR1 sequence that was previously shown to form
RNA foci in transfected cells (Sellier et al., 2010, 2013; Fig-
ure S4C). RNA FISH assays indicated that expanded CGG re-
peats embedded in the 50 UTR of FMR1 formed rare RNA foci
compared to the expanded CGG repeats without the surround-
ing FMR1 sequence (Figure S4D). Furthermore, RT-PCR per-
formed on nuclear and cytoplasmic fractions indicated that
most of the RNAs containing expanded CGG repeats embedded
within the 50 UTR of FMR1 are exported from the nucleus to the
cytoplasm (Figure S4E). In contrast, expanded CGG-repeat
RNAs without the FMR1 sequence are largely retained within
cell nuclei (Figure S4E). Both constructs present similar plasmid
backbones with strong polyadenylation signals (Figure S4C).
These results highlight the nuclear retention bias induced by us-
ing artificial constructs in which microsatellite repeats are sepa-
rated from their natural sequence context. Importantly, these
data also indicate that CGG expanded repeats embedded inScale bars, 50 mm. Sections were counter-stained with H&E staining.
(G) Representative image of 8-month-old control or bigenic Nestin-cre/full-length
(H) Kaplan-Meier survival curves of control (n = 10) or bigenic Nestin-cre/full-leng
Error bars indicate SEM. Student’s t test, * indicates p < 0.05, ** indicates p < 0.
338 Neuron 93, 331–347, January 18, 2017their natural FMR1 sequence are exported into the cytoplasm
and thus available for translation into FMRpolyG.
Expression of FMRpolyG Is Toxic for Neuronal Cells
Next, we investigated by which mechanisms the FMRpolyG pro-
tein may elicit neuronal cell dysfunction. Immunofluorescence
assays indicated that FMRpolyG first accumulates in the cyto-
plasm, where it forms aggregates. These aggregates then
migrate and form an inclusion within the cell nucleus in primary
mouse-embryonic neuronal cultures (Figure 5A). Similar results
were observed in HEK293 cells and when a smaller FLAG
epitope tag was used instead of GFP (Figures S5A and S5B).
Furthermore, immunoblotting indicated that FMRpolyG progres-
sively accumulates in the insoluble fraction of transfected cell
lysates, which is consistent with its propensity to form aggre-
gates (Figure S5C).
To identify the sequence driving FMRpolyG aggregation, we
cloned various deletion mutants of FMRpolyG expressing either
its N terminus with the glycine repeats or its C terminus in isola-
tion. To obtain comparable expression, all mutant constructs
were driven by an ATG (Figure S5D). Expression of the full-length
FMRpolyG protein in primary cultures of E18mouse cortical neu-
rons leads to nuclear aggregates associated with cell death (Fig-
ure 5B). Expression of the polyglycine stretch in isolation, with
the C terminus of FMRpolyG deleted, was sufficient to elicit ag-
gregation but was not overtly toxic. In contrast, expression of
GFP fused to the 42 amino acids constituting the C terminus of
FMRpolyG caused neuronal cell death without forming nuclear
aggregates (Figure 5B; Movies S3, S4, S5, and S6). Similar re-
sults were observed in Neuro2A cells (Figure S5E) and when
the GFP tag was replaced by the smaller FLAG tag (Figure S5F).
To confirm these results in ananimalmodel and test the toxicity
of FMRpolyG on a longer time period, we developed Drosophila
transgenic lines expressing either the full FMRpolyG protein or
the polyglycine stretch in isolation under a UAS promoter.
Toxicity was assessed by two separate assays. First, UAS
FMRpolyG-GFP and UAS polyG DCter-GFP flies, both ex-
pressed under an ATG initiator codon, were crossed with an
Act5c-Gal4 driver line, which leads to ubiquitous expression of
the transgene during development. Total progeny carrying either
the transgenes or a balancer chromosome were then quantified
over three independent crosses. Importantly, expression of the
full FMRpolyG was toxic and reduced progeny eclosion by half,
while the eclosion rate was only slightly reduced in flies express-
ing the polyglycine stretch in isolation (Figure 5C). To exclude any
potential bias due to random insertion effects, we generated and
analyzed various independent lines expressing either FMRpolyG
or its polyglycine stretch. As control, quantitative RT-PCR
showed similar expression of the FMRpolyGor polyglycine trans-
genes (Figure S5G). Importantly, all lines expressing FMRpolyG-
GFP showed reduced viability compared to GFP controls. In
contrast, the lines expressing the glycine repeats in isolation
consistently exhibited a milder phenotype (Figure S5H).FMR1 50 UTR mice.
th FMR1 50 UTR (n = 10) male and female mice.
01.
AB C
D
Figure 5. FMRpolyG Toxicity Is Influenced by
Its Carboxyl Terminus
(A) Immunofluorescence against FMRpolyG N ter-
minus and Lmnb1 in primary cultures of E18 mouse
cortical neurons transfected for the indicated time
period with expanded CGG repeats embedded
within the 50 UTR of FMR1 and fused to the GFP in
the glycine frame. Scale bars, 10 mm. Nuclei were
counter-stained with DAPI.
(B) Left, representative images of primary cultures of
E18mouse cortical neurons transfected with GFP or
ATG-driven FMRpolyG-GFP full-length or mutants.
Scale bars, 10 mm. Nuclei were counter-stained with
DAPI. Right, schemes of the mutant constructs of
FMRpolyG-GFP. The Nter construct corresponds to
the N-terminal part of FMRpolyG including its poly-
glycine repeats fused to the GFP. The Cter construct
corresponds to the last 42 amino acids of FMRpo-
lyG fused to the GFP. Lower, quantification of
neuronal cell viability of GFP-positive (n = 100 cells,
three independent transfections) transfected E18
mouse cortical neurons.
(C) Progeny eclosion ratio (n = 100, three indepen-
dent crosses) of Drosophila ubiquitously expressing
FMRpolyG, either full-length or deleted of its C ter-
minus compared to control driver line (Actin5C-
Gal4/+).
(D) Kaplan-Meier survival curve of Drosophila ex-
pressing FMRpolyG full-length or deleted of its
C terminus compared to control driver line (Tub5-
Gal4/+).
Error bars indicate SEM. Student’s t test, * indicates
p < 0.05, *** indicates p < 0.001.As a second measure of FMRpolyG toxicity, we crossed these
same transgenic fly lines to a Tubulin-Gal4 Geneswitch driver,
which expression is induced upon addition of mifepristone
(RU-486). As a control, adult transgenic flies reared off of RU-
486 drug exhibited no differences in viability from control flies,
indicating that insertion of the FMRpolyG or polyglycine trans-
genes had no deleterious effect. In contrast, transgenic flies
fed with RU-486, activating ubiquitous transgene expression,
showed a decrease in viability over time for FMRpolyG express-
ing flies (Figure 5D). Adult Drosophila expressing the polyglycine
stretch alone also presented a decrease in viability (Figure 5D);
however, their survival was significantly prolonged compared
to flies expressing the full FMRpolyG sequence. The difference
of toxicity of the polyglycine stretch in isolation between cell cul-
ture and Drosophila is probably due to the longer time frame and
in vivo nature of the Drosophila studies. Overall, these results
demonstrate that expression of FMRpolyG is pathogenic, with
its polyglycine stretch driving aggregation and with both polygly-
cine and its C terminus contributing to toxicity in vivo.FMRpolyG Interacts with LAP2b and
Alters the Nuclear Lamina
To identify FMRpolyG binding proteins, we
performed a tandem tag purification of HA-
FLAG-tagged FMRpolyG transfected into
Neuro2A cells followed by nano-LC-MS/
MS analysis of associated proteins. Thisapproach identified various FMRpolyG-associated proteins
(Table S1), including Lap2b (Figure 6A). Lamina-associated poly-
peptide 2 (LAP) alpha and beta are two isoforms of the LAP2 pro-
tein that differ in their C-termini; these isoforms originate from
alternative splicing of the TMPO pre-mRNA. LAP2a is diffusely
localized in the nucleus, while LAP2b carries a transmembrane
domain in its C terminus that anchors it to the inner nuclear mem-
brane (Furukawa et al., 1995). LAP2b interacts with lamin B1 and
B2 and helps to organize these proteins near the nuclear inner
membrane. Consequently, alteration of LAP2b results in disorga-
nization of the nuclear lamina architecture (Dubinska-Magiera
et al., 2016; Gant et al., 1999).
Co-immunoprecipitation studies confirmed the association of
LAP2b with HA-FLAG-tagged FMRpolyG, but not with the poly-
glycine stretch in isolation (Figure 6B). Similar results were
observed when a GFP tag was used instead of the double
FLAG-HA tag (Figure 6C). An interaction between LAP2b and
FMRpolyG raises questions of whether translation of the
expanded CGG repeats in FXTAS may alter the localization orNeuron 93, 331–347, January 18, 2017 339
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the function of LAP2b. Expression of FMRpolyG-GFP in primary
cultures of cortical neurons from mouse embryo indicated that
FMRpolyGrecruitsendogenousLap2b innuclearaggregates (Fig-
ure 6D). Similar results were observed in HEK293 cells and when
the GFP was replaced by a smaller FLAG tag (Figure S6A). In
contrast, a construct containing only the polyglycine stretch of
FMRpolyG did not alter Lap2b localization, suggesting that the
C-terminal part of FMRpolyG is important for interaction and de-
localization of LAP2b (Figure 6D). Immunohistochemistry assays
confirmed that endogenousLap2b localizes innuclear aggregates
in brain sections of the full 50 UTR FMR1 transgenicmice, unlike in
mutant 50 UTR mice (Figure 6E). These aggregates of Lap2b co-
localized with FMRpolyG inclusions (Figure 6F). We next tried to
confirm these results in brain sections of individuals with FXTAS.
However, LAP2b immunohistochemistry was of poor quality on
human autopsied material. We nevertheless observed some
LAP2b aggregates in cerebellum sections as well as in the
hippocampal area of FXTAS individuals (Figures 6G and S6B).
Furthermore, immunofluorescence assays indicated that LAP2b
co-localized with FMRpolyG inclusions in individuals with FXTAS,
but not in age-matched control individuals (Figure 6H).
Alteration of LAP2b results in disorganization of the nuclear
lamina (Gant et al., 1999; Dubinska-Magiera et al., 2016). Thus,
we next investigated the consequences of FMRpolyG expres-
sion on the architecture of the nuclear lamina. Expression of 99
CGG repeats embedded within the 50 UTR of FMR1 fused in
the glycine framewith either a GFP or a FLAG tag in HEK293 cells
resulted in disorganization of the nuclear lamina, as evidenced
by alterations of the lamin B1 labeling (Figure S6C). Similarly,
expression of FMRpolyG-GFP in primary cultures of mouse em-
bryonic cortical neurons altered lamin B1 nuclear organization
(Figure S6D). Furthermore, and as reported previously with lamin
A (Iwahashi et al., 2006), the localization of lamin B1 was altered
in brain sections of FXTAS compared to controls (Figure S6E).
LAP2b and Nuclear Lamina Are Altered in Neurons
Differentiated from FXTAS iPS Cells
Alterations of the nuclear lamina were observed in autopsied
samples that may represent an end stage of the disease. ToFigure 6. FMRpolyG Interacts with LAP2b and Alters Its Nuclear Local
(A) Silver staining of proteins captured through consecutive anti-FLAG and anti-HA
FLAG-HA-tagged FMRpolyG, either full-length or deleted of its C terminus.
(B) Immunoblotting against endogenous Lap2b protein of tandem-tag purified pr
FMRpolyG, either full-length or deleted of its C terminus.
(C) Immunoblotting against the HA or GFP tags of HA-tagged immunoprecipitated
HA-LAP2b and ATG-driven FMRpolyG-GFP, either full-length or deleted of its N
(D) Left, GFP fluorescence and immunofluorescence against endogenous Lap2b
CGG repeats embedded within the 50 UTR of FMR1 either full-length or deleted o
counterstained with DAPI. Right, quantification of co-localization of Lap2bwith GF
independent transfections).
(E) Immunohistochemistry against Lap2b of cerebellum, hippocampal and hypo
50 UTR transgenic mice. Sections were counter-stained with H&E staining.
(F) Left, immunofluorescence against FMRpolyG N terminus and Lap2b on hipp
50 UTR transgenic mice. Nuclei were counter-stained with DAPI. Right, quantificat
mutant FMR1 50 UTR transgenic mice (n = 50 neurons, three mice).
(G) Immunohistochemistry against LAP2b of cerebellum areas of FXTAS individu
(H) Immunofluorescence against FMRpolyGN terminus and LAP2b on brain sectio
counter-stained with DAPI.
Scale bars, 10 mm. Error bars indicate SEM. Student’s t test, *** indicates p < 0.overcome this potential bias, we developed human induced
pluripotent stem (iPS) cells derived from fibroblasts from two
age-matched controls and three different FXTAS patients with
expansion of 84, 90, and 99 CGG repeats. These iPS cells
were differentiated into homogeneous populations of telence-
phalic neurons with no obvious difference of growth or differen-
tiation between FXTAS and controls iPS cells (Figure S7A). As
observed previously (Liu et al., 2012), expression of FMR1
mRNA was increased 2- to 3-fold in differentiated neurons
derived from FXTAS iPS cells compared to controls (Figure S7B).
This is consistent with the increased levels of FMR1 mRNA
observed in carriers of a CGG pre-mutation (Tassone et al.,
2000, 2007; Kenneson et al., 2001).
Immunofluorescence assays detected accumulation of nu-
clear aggregates of FMRpolyG in FXTAS neurons, but not in con-
trol neurons (Figure 7A). FMRpolyG aggregates accumulated
over time post-differentiation, with 5% to 10% of neurons exhib-
iting small FMRpolyG aggregates at 20 days of differentiation,
while 20% to 30% of neurons present FMRpolyG nuclear aggre-
gates after 40 days of differentiation (Figure S7C). In contrast,
RNA foci of expanded CGG repeats were rare or absent in
FXTAS neurons at 40 days post-differentiation (Figure S7C).
Importantly, immunofluorescence analysis revealed that endog-
enous LAP2b loses its normal localization and forms nuclear
inclusions that co-localize with FMRpolyG in neurons differenti-
ated from FXTAS iPS cells (Figure 7A). Furthermore, aggregation
of LAP2b and FMRpolyG were associated with disorganization
of the nuclear lamina structure, as shown by alteration of the
lamin B1 labeling in FXTAS neurons (Figure 7B). In contrast, neu-
rons differentiated from iPS cells of control individuals exhibited
normal LAP2b and lamin B1 localization (Figures 7A and 7B).
Overexpression of LAP2 Rescues Neuronal Cell Death
Caused by FMRpolyG
Finally, LAP2b overexpression was sufficient to rescue the cell
death induced by transfection of FMRpolyG-GFP in neuronal
cells (Figure 7C). Consistent with LAP2b binding to the C-termi-
nal part of the FMRpolyG protein, expression of LAP2b also
rescued cell death caused by expression of the FMRpolyGization
affinity purification steps from N2A cells transfected for 24 hr with ATG-driven
oteins from N2A cells transfected for 24 hr with ATG-driven FLAG-HA-tagged
proteins from the soluble lysate fraction of N2A cells transfected for 24 hr with
or C terminus.
in primary cultures of E18 mouse cortical neurons transfected with expanded
f FMRpolyG C terminus and fused to the GFP in the glycine frame. Nuclei were
P inclusions in transfected E18mouse cortical neurons (n = 100 neurons, three
thalamic areas of 9-month-old bigenic CMV-cre/full-length or mutant FMR1
ocampal areas of 9-month-old bigenic CMV-cre/full-length or mutant FMR1
ion of co-localization of Lap2bwith FMRpolyG in bigenic CMV-cre/full-length or
al or age-matched control. Sections were counter-stained with H&E staining.
ns (hippocampal area) of FXTAS patients or age-matched controls. Nuclei were
001.
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Figure 7. LAP2b Rescues Neuronal Cell Death Induced by FMRpolyG
(A) Upper, immunofluorescence against FMRpolyG N terminus and LAP2b on neuronal cultures differentiated 40 days from iPS cells of FXTAs patients or control
individuals. Lower, quantification of LAP2b co-localization with FMRpolyG in neurons from iPSC of FXTAS and control individuals (n = 100 neurons, three in-
dependent cultures).
(legend continued on next page)
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Figure 8. A Working Model for Pathogenicity
in FXTAS
Expanded CGG repeats are translated into a poly-
glycine-containing protein, FMRpolyG, through
initiation to a non-canonical ACG codon located
upstream of the CGG repeats. In FXTAS, higher
expression of FMR1 mRNA and increased trans-
lation and stability of the expanded CGG repeats
result in accumulation of FMRpolyG in nuclear ag-
gregates that sequester the LAP2b protein and alter
the nuclear lamina architecture.C terminus in isolation (Figure 7C). As controls, expression of
LAP2b had no effect on neuronal survival in control GFP-trans-
fected cells or in neurons expressing the polyglycine fragment
in isolation. Similar results were observed when the GFP was re-
placed by a smaller FLAG tag (Figure S7D). Overall, these data
suggest a mechanism by which FMRpolyG can elicit toxicity
(Figure 8), and they provide an explanation for previously
observed nuclear lamina disorganization in FXTAS patients (Aro-
cena et al., 2005; Iwahashi et al., 2006; Hoem et al., 2011).
DISCUSSION
Previous studies have demonstrated that FXTAS is caused by
expression of mutant RNAs containing expanded CGG repeats
(Willemsen et al., 2003; Jin et al., 2003; Arocena et al., 2005; Ha-
shem et al., 2009; Entezam et al., 2007; Hukema et al., 2014,
2015). However, whether expanded CGG repeats are patho-
genic through an RNA gain-of-function mechanism or through
translation into a toxic protein was unclear. Using novel mouse
models with or without FMRpolyG expression, our study sug-
gests a direct role for FMRpolyG in CGG-repeat-associated(B) Upper, immunofluorescence against FMRpolyG N terminus and LMNB1 on neuronal cultures differentiate
individuals. Lower, quantification of lamin B1 alteration in FMRpolyG-positive cells in neurons from iPSC of F
independent cultures).
(C) Cell viability of neuronal N2A cells transfected (n = 3 transfections) with ATG-driven FMRpolyG-GFP eithe
a plasmid expressing RFP as control or Ha-tagged LAP2b.
Error bars indicate SEM. Student’s t test, *** indicates p < 0.001.toxicity. This study confirms in a mamma-
lian system previous results obtained in
Drosophila (Todd et al., 2013). Moreover,
we found that FMRpolyG disrupts nuclear
lamina architecture through binding to the
nuclear envelope protein LAP2b. These
finding are reminiscent of Amyotrophic
Lateral Sclerosis and Frontotemporal
Dementia (ALS-FTD) in which expanded
GGGGCC repeats in the C9ORF72 gene
(Renton et al., 2011; DeJesus-Hernandez
et al., 2011) are RAN translated into patho-
genic di-peptide-containing proteins (Ash
et al., 2013; Mori et al., 2013; Zu et al.,
2013) that disrupt nucleocytoplasmic
transport (Zhang et al., 2015, 2016; Frei-
baum et al., 2015; Jovicic et al., 2015).In contrast to the RAN translation of CAG expanded repeats in
the polyalanine frame, which was shown to initiate within the
expanded repeats (Zu et al., 2011), our work confirms that
expression of FMRpolyG depends largely on initiation at a
near-cognate codon located upstream of the CGG repeats
(Todd et al., 2013; Kearse et al., 2016). Moreover, we provide
mass spectrometry data indicating that the N-terminal amino
acid of FMRpolyG is a methionine in mammalian cells, suggest-
ing a canonical mechanism of initiation with altered start-codon
fidelity. Our data also suggest that expanded CGG repeats
belong to a potential small ORF translated upstream of the
main FMRP ORF. However, FMRpolyG is hardly detectable
below 70 CGG repeats. This is consistent with the difficulties
in detecting small proteins below 10 kDa, but also with
the increased expression of mutant CGG RNA in carriers of
pre-mutation over 70 CGG repeats (Tassone et al., 2000, 2007;
Kenneson et al., 2001) and with the proposed increase in ribo-
somal stalling at a CGG hairpin structure, which would promote
translation initiation to near-cognate codons located upstream
of the CGG repeats (Todd et al., 2013; Kearse et al., 2016).
Reduced expression of FMRpolyG below 70 CGG repeats mayd 40 days from iPS cells of FXTAs patients or control
XTAS and control individuals (n = 100 neurons, three
r full-length or deleted of its N or C terminus and with
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provide some molecular basis for the threshold of severity and
incomplete penetrance observed in FXTAS, as most of pre-
mutation alleles contain less than 70 CGG repeats (review in
Tassone et al., 2012). We also noted that translation of the
FMRpolyG uORF reduces the expression of FMRP; thus, expres-
sion of FMRpolyG may contribute to the decrease of FMRP
expression observed in FXTAS individuals (Tassone et al.,
2000, 2007; Kenneson et al., 2001). However, other mechanisms
may also contribute to the decreased expression of FMRP in
FXTAS, including the increased ribosome stalling observed
with expandedCGGRNA hairpin structure (Feng et al., 1995; Pri-
merano et al., 2002). Ribosome profiling and bioinformatics
analyses reveal that upstream ORFs (uORFs) are common in
mammalian mRNAs and can initiate at non-canonical codons
(Calvo et al., 2009; Ingolia et al., 2011; Fritsch et al., 2012; Ji
et al., 2015). Mutations in uORFs are known to cause human dis-
ease, mostly by altering the expression of their downstream
ORFs (reviewed in Barbosa et al., 2013). In contrast, we propose
here that FXTAS is characterized by a mutation extending the
length of a uORF and resulting in expression of a toxic, polygly-
cine-containing protein, FMRpolyG. This model is reminiscent of
expansion of tri-nucleotide repeats in ORFs, resulting in expres-
sion of pathogenic polyglutamine- or polyalanine-containing
proteins (reviewed in Nelson et al., 2013).
Of interest, a pathogenic mechanism in which expansion of
nucleotide repeats into a uORF results in expression of a toxic
protein may apply to other diseases. For example, aggregates
of FMRpolyG were observed in ovarian stromal cells of a woman
with Fragile-X-associated primary ovarian insufficiency (FXPOI),
caused, like FXTAS, by expanded CGG repeats in the FMR1
gene (Buijsen et al., 2016). Similarly, it is striking to note that
expanded GGGGCC repeats, which are located upstream of
the C9ORF72 ORF and are the main genetic cause of ALS-
FTD, are in frame with an upstream, CTG near-cognate codon
in a correct Kozac sequence (gctCTGg) to encode a glycine
alanine-polypeptide, which is the most common dipeptide-
repeat protein detected in individuals with ALS-FTD (Mackenzie
et al., 2015).While hypothetical, extending further the FXTAS and
fragile X model to C9ORF72 might predict that long expansions
of GGGGCC repeats in tissues prone to somatic expansions
would be transcriptionally silent due to epigenetic modification
of the promoter, while shorter expansions in tissues prone to
repeat contraction would be transcribed and translated.
One of the main conclusions of this work is that mice express-
ing FMRpolyG develop a locomotor phenotype with reduced
longevity, while mice expressing only the expanded CGG repeat
RNA are indistinguishable from control mice. These results sug-
gest that accumulation of RNA with expanded CGG repeats or
RAN translation initiating within these repeats is not overly path-
ogenic inmice, at least in the time frame of our study.While infor-
mative on the pathogenicity of FMRpolyG, these mouse models
present some limitations. Notably, our behavioral and locomotor
investigations were limited to the first 3 months of life, because
animals expressing FMRpolyG in the brain develop obesity and
grow immobile at around 6 months of age. This is in contrast
to an individual with FXTAS who do not develop morbid obesity.
Furthermore, no FMRpolyG-expressing mice survived past
1 year of age, impairing our ability to observe potential neurode-344 Neuron 93, 331–347, January 18, 2017generation at later ages. As transgene expression is driven by an
artificial promoter in these mice, it is likely that their premature
death is due to a non-physiological level and/or distribution of
transgene expression that may be unrelated to what occurs in
FXTAS. Thus, analysis of potential Purkinje cell dropout and
ataxia at old age will require specific expression of FMRpolyG
in mouse cerebellum.
Direct comparison of these novel mice with previous models
of FXTAS expressing either mRNA with 90 CGG repeats and
FMRpolyG protein (Willemsen et al., 2003; Hashem et al., 2009;
Hukema et al., 2015) or only mRNA with 118 CGG repeats (En-
tezam et al., 2007; Qin et al., 2011) is difficult, as thesemice either
express endogenous levels of FMR1 mRNA with knockin of the
expanded CGG repeats into the endogenous Fmr1 gene (Willem-
sen et al., 2003; Entezam et al., 2007) or express expanded
repeats in more restricted brain regions than the mouse models
reportedhere (Hashemetal., 2009;Hukemaetal., 2015). It is note-
worthy that knockin mice with expanded CGG repeats, which do
not express FMRpolyG due to presence of a stop codon located
upstream of the CGG repeats (Entezam et al., 2007; Todd et al.,
2013), exhibit some Purkinje cell dropout at 2 years of age but
exhibit no ataxia or rotarod deficiency and only a mild behavioral
phenotype with hyperactivity, reduced anxiety, and some subtle
deficits in social interaction (Entezam et al., 2007; Qin et al.,
2011). These behavioral alterations are similar to those observed
inFmr1 knockoutmousemodels; this suggests that theymight be
caused, in part, by the reduced expression of FMRP observed in
this CGG knockin mouse model (Qin et al., 2011). In contrast, the
mildPurkinje cell dropout observedat 2 yearsof age in thatmouse
model (Entezamet al., 2007) couldbecausedbyexpressionof the
mutant RNA containing expanded CGG repeats and/or RAN
translation from these repeats. We failed to detect RNA foci of
expanded CGG repeats or nuclear aggregates of FMRpolyA in
our mouse models or in neurons from human iPS cells derived
from individuals with FXTAS. However, this could originate from
technical issues, notably a lack of sufficient sensitivity of our
FISH probes of our FMRpolyA antibody. It is also possible that
CGG RNA foci and FMRpolyA appear at a later stage of the dis-
ease. Thus, whether accumulation of CGG RNA and/or RAN
translation of CGG repeats into FMRpolyA might contribute to
pathogenicity in FXTAS remains an open question.
Finally, we found that toxicity of FMRpolyG ismediated at least
in part through sequestration of the LAP2b protein into nuclear
aggregates, leading to disruption of the nuclear lamina archi-
tecture and neuronal cell death. These data provide a molecular
mechanism for the previously reported nuclear lamina disorgani-
zation in FXTAS (Arocena et al., 2005; Iwahashi et al., 2006;Hoem
et al., 2011). However, the cell toxicity rescue observed upon
overexpression of LAP2b may also originate from high levels of
LAP2b blocking the interaction of FMRpolyG with various other
proteins. Thus, it is possible that FMRpolyGmediates its toxic ef-
fects through more than one mechanism and/or protein partner.
Notably, LAP2b regulates gene expression through association
with various transcription factors as well as with DNA and with
the DNA-binding protein BAF1 (barrier to auto-integration fac-
tor 1) protein (Shumaker et al., 2001). It remains to be determined
whether FMRpolyG alters this LAP2 transcriptional regulatory
activity. Also, proteomic analysis indicates that FMRpolyG pulls
down various other proteins, including cytoskeleton, mitochon-
drial, and proteasome proteins. Some of these proteins are
good candidates to contribute to the mitochondrial alterations
that have been observed in FXTAS (Ross-Inta et al., 2010; Kaplan
et al., 2012; Hukema et al., 2014). Similarly, FMRpolyG appears
critical for elicitation of ubiquitin proteasome impairment when
expressed in cells or Drosophila (Oh et al., 2015). Further investi-
gations will be needed to test the potential pathological effect
of FMRpolyG on mitochondria, protein degradation mecha-
nisms, and cell cytoskeleton in FXTAS.
In conclusion, the FMR1 gene encodes for at least two
different proteins, FMRpolyG and FMRP, whose levels are
inversely modulated by the size of the CGG repeat expansion
and which are involved in two different genetic diseases, FXTAS
and fragile X syndrome.
EXPERIMENTAL PROCEDURES
Human Samples
All brain samples were obtained from the FXTAS brain repository at the UC
Davis School of Medicine with the informed consent of individuals and were
approved by the Institutional Review Board of the University of California,
Davis. Patients have been described previously (Cases LR, 58-02-WD and
1007-05-HP from Greco et al., 2006 and Pretto et al., 2014). Fibroblasts of
three FXTAS male individuals with confirmed pre-mutation of 84, 90, and 99
CGG repeats were obtained with the informed consent of individuals and
approved by the Institutional Review Board of the Hospital La Pitie´ Salpeˆtrie`re.
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